Comparison

Retatrutide vs
cagrilintide

Two investigational peptides from two companies, acting on different hormone receptors. The same questions asked of both, dated 18 November 2026, with no winner and no efficacy figures.

Short answerCompound research · 7 min read · Updated 18 Nov 2026

Retatrutide and cagrilintide are different investigational peptides. Retatrutide, from Eli Lilly, activates the GIP, GLP-1 and glucagon receptors and has been tested on its own. Cagrilintide, from Novo Nordisk, is a long-acting amylin analogue tested mostly with semaglutide, as CagriSema. Neither is approved in the US or the EU, and we found no trial comparing them.

Key takeaways

  • Retatrutide is Eli Lilly’s investigational peptide that activates the GIP, GLP-1 and glucagon receptors; cagrilintide is Novo Nordisk’s investigational long-acting analogue of amylin, a hormone made by the pancreas.
  • The published retatrutide trials we found gave it alone. Most of cagrilintide’s phase 3 data come from CagriSema, its combination with semaglutide, the active ingredient of the prescription medicines Ozempic and Wegovy.
  • We found no trial comparing the two; the one study we found that gave both used them together, in rats (PubMed and ClinicalTrials.gov, 18 Nov 2026).
  • FDA says both “cannot be used in compounding under federal law” and have “not been found safe and effective for any condition”.
  • Lilly plans to seek US approval of retatrutide in the first quarter of 2027; Novo Nordisk filed for CagriSema in December 2025 and expects an FDA decision in the fourth quarter of 2026.

01What is retatrutide?

Retatrutide, development code LY3437943, is a single peptide that activates the receptors for three hormones: GIP, GLP-1 and glucagon. A 2026 review in Pharmaceutics describes it as a 39-amino-acid peptide built on a GIP-based sequence, with a fatty acid attached (lipidated). Eli Lilly developed it and funded each of its clinical trials cited here.

The published trials we cite gave it as a single drug, not in a combination product, to adults with obesity or overweight, some with type 2 diabetes. It is investigational: the TGA wrote on 5 November 2026 that it “has not been approved by the TGA or any comparable international regulator”. The full profile: what is retatrutide?

02What is cagrilintide?

Cagrilintide is a long-acting analogue of amylin, a hormone made by the pancreas. Novo Nordisk scientists described its development in 2021 as a “stable, lipidated long-acting amylin analogue”, and the design paper of the REDEFINE 3 trial calls it an amylin receptor agonist.

Most of its late-stage testing is as CagriSema, a fixed combination with semaglutide. Semaglutide is a GLP-1 receptor agonist and the active ingredient of the prescription medicines Ozempic and Wegovy. REDEFINE 1 also had a smaller group given cagrilintide alone, and Novo Nordisk has registered phase 3 trials of cagrilintide on its own, none of which has posted results (ClinicalTrials.gov, 18 Nov 2026). The full profile: what is cagrilintide?

03How do retatrutide and cagrilintide differ?

The same questions for both, checked on 18 November 2026.

QuestionRetatrutideCagrilintide
What it isA single peptide that activates three hormone receptorsA long-acting analogue of amylin, a hormone made by the pancreas
ReceptorsGIP, GLP-1 and glucagon receptorsAmylin receptors; the REDEFINE 3 design paper calls it an amylin receptor agonist
Structure39 amino acids on a GIP-based sequence, lipidated (2026 review)A lipidated amylin analogue (Novo Nordisk scientists, 2021)
Developer, who funded the trialsEli LillyNovo Nordisk
How it has been testedOn its own, in every published trial we listMostly with semaglutide, as CagriSema; alone in a 2021 phase 2 trial and in single-drug arms of some phase 3 trials, such as REDEFINE 1
Phase 3 records on ClinicalTrials.gov, 18 Nov 202614, all sponsored by Lilly: 5 completed, 9 active or recruiting23, all sponsored by Novo Nordisk: 10 completed, 13 active, recruiting, not yet recruiting or withdrawn
Phase 3 programme in overweight and obesityTRIUMPH (retatrutide alone)REDEFINE (CagriSema)
Longest published phase 3 trials80 weeks: TRIUMPH-1 and TRIUMPH-2, published 29 Sep 202668 weeks, among them REDEFINE 1 and REDEFINE 2, online 22 Jun 2025
Heart-outcomes trialTRIUMPH-Outcomes, about 10,000 adults; primary completion expected Feb 2029 (NCT06383390)REDEFINE 3, 7,076 adults; primary completion expected Sep 2027 (NCT05669755)
Evidence tierT1, investigational: randomised trials of Lilly’s productT1, investigational: randomised trials of Novo Nordisk’s product, mostly in combination
United StatesNot approved. Lilly plans to submit an application in the first quarter of 2027Not approved. Novo Nordisk filed for CagriSema in Dec 2025 and expects a decision in the fourth quarter of 2026
European UnionNo EU-wide authorisation: no medicine containing it in EMA’s data (18 Nov 2026)No EU-wide authorisation: no medicine containing it in EMA’s data (18 Nov 2026)
FDA on compounding“cannot be used in compounding under federal law”“cannot be used in compounding under federal law”
WADA Prohibited ListNot named on the 2026 or 2027 List; WADA’s 2027 notes say an unnamed peptide “may still be prohibited”Not named on the 2026 or 2027 List; WADA’s 2027 notes say an unnamed peptide “may still be prohibited”
Regulator actions on products sold onlineFDA warning letters (Dec 2024 to Aug 2026); MHRA (Oct 2025, Oct 2026); TGA (Sep 2026, Nov 2026)FDA warning letters (Dec 2024, Mar 2026); no MHRA release names it (GOV.UK search, 18 Nov 2026)

How to read the table. The two drugs were not tested the same way. Retatrutide’s phase 3 data are for retatrutide alone; most of cagrilintide’s phase 3 data are for cagrilintide combined with semaglutide. Their trials also differ in length, population and comparison, so their results cannot be lined up as if they described the same thing. We give no efficacy figures for either: neither is approved, and we do not repeat efficacy figures for investigational drugs. How we grade evidence: evidence grades.

04Has any research compared retatrutide and cagrilintide?

We found no trial that compares them. On 18 November 2026, ClinicalTrials.gov returned no study with both as interventions, and PubMed returned 22 records naming both in the title or abstract.

One animal study gave them together. A 2026 study from the University of Copenhagen gave retatrutide and cagrilintide together to diet-induced obese male rats, against each one alone and against other drug combinations. It tested them as a pair, not as alternatives, in rats (T3), and it tells us nothing about people.

The other 21 records discuss them among other drugs. They are reviews, systematic reviews and network meta-analyses. A network meta-analysis, such as a 2026 BMJ review of 262 trials of 19 drugs, compares drugs indirectly, across different trials with different populations and durations. That is not head-to-head evidence. We do not reproduce their rankings or estimates.

05How do regulators treat retatrutide and cagrilintide?

Neither is an approved medicine in the US or the EU as of 18 November 2026. FDA names them in the same sentence.

FDA. FDA’s page on unapproved GLP-1 drugs (content current 1 October 2026) says: “Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition.” Drugs@FDA lists no application for either (openFDA search, 18 November 2026).

Where each stands with FDA. Lilly said on 29 September 2026 that it “plans to submit a Biologics License Application (BLA) in Q1 2027” for retatrutide. Novo Nordisk filed a New Drug Application for CagriSema in December 2025, and on 20 October 2026 it said that “A decision is expected in Q4 2026”, that “CagriSema is not approved for use in the United States” and that “Safety and efficacy are not established.” A filing asks FDA to review the evidence; it is not an approval. US drug law and peptides: are peptides legal in the US?

Products sold online. On 10 December 2024 FDA wrote to an online seller that its “Retatrutide” and “Cagrilintide” products, listed alongside semaglutide, tirzepatide and mazdutide products, were unapproved new drugs, despite labels reading “RESEARCH USE ONLY” and “INTENDED AS A RESEARCH CHEMICAL ONLY”. Later letters named retatrutide (four sellers, 24 August 2026) and cagrilintide (another seller, 31 March 2026). For retatrutide, two more regulators have acted. The MHRA said on 15 October 2026 that “Retatrutide has not been authorised for use in the UK.” The TGA wrote on 5 November 2026 that tested products from one brand “contained less retatrutide than stated on the label, with significant variation between samples”. A GOV.UK search on 18 November 2026 found no MHRA release that names cagrilintide.

A lab report can show what one tested sample contained. It cannot turn that sample into the product either company tested, or into an approved medicine. What a research-use label does and does not mean: research use only, explained. Documented cases: contamination and mislabeling.

06What we don’t know about retatrutide and cagrilintide

  • How they would compare in people. No trial has tested one against the other, and their trials were built differently: retatrutide alone, cagrilintide mostly with semaglutide.
  • Whether FDA will approve either, and when. Novo Nordisk expects a decision on CagriSema in the fourth quarter of 2026; Lilly plans its retatrutide filing for the first quarter of 2027.
  • What the heart-outcomes trials will show. TRIUMPH-Outcomes and REDEFINE 3 are listed as active, not recruiting.
  • What the phase 3 trials of cagrilintide on its own will report. None has posted results (ClinicalTrials.gov, 18 Nov 2026).
  • What any vial sold online under either name contains. A lab report shows only what the tested sample held.

This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.

RefSources

  1. U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Web page, content current as of 1 Oct 2026; read 18 Nov 2026. www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-u…
  2. U.S. Food and Drug Administration. Warning letter 695607 (Summit Research Peptides). Warning letter, 10 Dec 2024; read 18 Nov 2026. www.fda.gov/inspections-compliance-enforcement-and-criminal-…
  3. ClinicalTrials.gov. Phase 3 studies with retatrutide (14 records) and with cagrilintide (23 records) as interventions; no record with both; NCT06383390 and NCT05669755. Registry searches via API v2, 18 Nov 2026. clinicaltrials.gov/search?intr=retatrutide%20AND%20cagrilint…
  4. Mateescu DM, Capraru ID, Enache B, et al. Retatrutide as a unimolecular GIP/GLP-1/glucagon receptor tri-agonist: molecular design, pharmaceutical development and critical interpretation of emerging phase 3 evidence. Pharmaceutics, 2026;18(10):1277. PMID 42942810 (full text read 18 Nov 2026). pmc.ncbi.nlm.nih.gov/articles/PMC13708278/
  5. Kruse T, Hansen JL, Dahl K, et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem, 2021;64(15):11183–11194. PMID 34288673. pubmed.ncbi.nlm.nih.gov/34288673/
  6. Cavender MA, Jastreboff AM, Cheng AYY, et al. Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3). Am Heart J, online 6 Oct 2026. PMID 42838477. pubmed.ncbi.nlm.nih.gov/42838477/
  7. Garvey WT, Blüher M, Osorto Contreras CK, et al.; REDEFINE 1 Study Group. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N Engl J Med, 2025;393(7):635–647 (online 22 Jun 2025). PMID 40544433. pubmed.ncbi.nlm.nih.gov/40544433/
  8. Davies MJ, Bajaj HS, Broholm C, et al.; REDEFINE 2 Study Group. Cagrilintide–semaglutide in adults with overweight or obesity and type 2 diabetes. N Engl J Med, 2025;393(7):648–659 (online 22 Jun 2025). PMID 40544432. pubmed.ncbi.nlm.nih.gov/40544432/
  9. World Anti-Doping Agency. The Prohibited List 2026 and 2027 (no entry for retatrutide, LY3437943 or cagrilintide). International Standard (2026 List in force since 1 Jan 2026; 2027 List takes effect 1 Jan 2027); both PDFs searched 18 Nov 2026. www.wada-ama.org/en/prohibited-list
  10. World Anti-Doping Agency. 2027 Prohibited List: summary of major modifications and explanatory notes (S0, non-approved substances). Undated (the file name carries 17 Aug 2026); published with the 2027 List on 21 Sep 2026; read at wada-ama.org 18 Nov 2026. www.wada-ama.org/sites/default/files/2026-09/2027_list_expla…
  11. Jastreboff AM, Kaplan LM, Davies MJ, et al.; TRIUMPH-1 Investigators. [TRIUMPH-1 phase 3 trial report.] N Engl J Med, 2026;395(18):1781–1793 (online 29 Sep 2026). PMID 42814954. pubmed.ncbi.nlm.nih.gov/42814954/
  12. Petersen J, Merrild C, Holm SK, et al. [Rat study giving retatrutide and cagrilintide together.] Nat Metab, 2026;8(10):2069–2083. PMID 42744908. pubmed.ncbi.nlm.nih.gov/42744908/
  13. Nong K, Shi Q, Xie X, et al. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. BMJ, 2026;394:e372161. PMID 42419792. pubmed.ncbi.nlm.nih.gov/42419792/
  14. European Medicines Agency. Medicines data export (centrally authorised medicines), timestamp 18 Nov 2026, 2,765 records. Dataset; searched 18 Nov 2026. www.ema.europa.eu/en/documents/report/medicines-output-medic…
  15. Medicines and Healthcare products Regulatory Agency. Counterfeit weight loss pens worth £2 million seized by MHRA and West Midlands Police. Press release, 15 Oct 2026; read 18 Nov 2026 (GOV.UK search for cagrilintide: no results). www.gov.uk/government/news/counterfeit-weight-loss-pens-wort…
  16. Therapeutic Goods Administration. TGA testing finds unapproved peptides do not contain what their labels claim. Safety advisory, 5 Nov 2026; read on the Internet Archive capture of 15 Nov 2026. www.tga.gov.au/safety/safety-monitoring-and-information/safe…
  17. Eli Lilly and Company. [Press release on the TRIUMPH-2 results and the planned US submission.] Press release, 29 Sep 2026; read on PR Newswire 18 Nov 2026. www.prnewswire.com/news-releases/lillys-triple-agonist-retat…
  18. Novo Nordisk. [Announcement of a REDEFINE 1 analysis, with CagriSema’s US regulatory status.] Company announcement, 20 Oct 2026; read 18 Nov 2026. www.novonordisk.com/news-and-media/news-and-ir-materials/new…

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

Is retatrutide the same as cagrilintide?

No. They are different investigational peptides from different companies. Retatrutide, from Eli Lilly, activates the GIP, GLP-1 and glucagon receptors; cagrilintide, from Novo Nordisk, is an analogue of amylin, a hormone made by the pancreas.

Do retatrutide and cagrilintide act on the same receptors?

No. Retatrutide activates the GIP, GLP-1 and glucagon receptors. Cagrilintide acts on amylin receptors; the GLP-1 drug in CagriSema is semaglutide.

Has any study compared retatrutide and cagrilintide?

We found no trial comparing them in people (ClinicalTrials.gov and PubMed, 18 Nov 2026). One 2026 study gave them together to rats, and network meta-analyses compare them only indirectly, across different trials.

Is either retatrutide or cagrilintide approved?

No. Neither is approved in the US or the EU as of 18 November 2026. Novo Nordisk expects an FDA decision on CagriSema in the fourth quarter of 2026; Lilly plans to file for retatrutide in the first quarter of 2027.

What is CagriSema?

Novo Nordisk’s investigational fixed combination of cagrilintide with semaglutide, the active ingredient of the prescription medicines Ozempic and Wegovy. Most of cagrilintide’s phase 3 data come from CagriSema.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page